Entera Bio Ltd.

ENTX

$2.95

+1.03%

N/A+$0.03

Healthcare

Biotechnology

NASDAQ

Negociación activa

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large ...

Métricas clave de ENTX

Instantánea

Último / TTM · 6 periodos

Capitalización

$145.41M

ROCE

-82.9%

EV / EBITDA

-9.43x

+0.7% YoY

Rendimiento FCF

-7.8%

+0.5% YoY

Ciclo de conversión de efectivo

-13991.7d

Ratio corriente

8.98

Resumen rápido

TTM —

Sin señales de riesgo importantes en las métricas seleccionadas.

Métricas clave

Último / TTM · 6 periodos

Tendencia de valoración

Tendencia de valoración table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$73.70M	$21.03M	$17.40M	$79.82M	$89.61M	$145.41M
Enterprise ValueCompany value including debt and cash adjustments.	$49.11M	$8.81M	$6.78M	$71.43M	$82.99M	$134.52M
EV / SalesHow many dollars investors pay per dollar of sales.	86.00x	65.76x	0.00x	394.64x	1976.02x	0.00x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-4.04x	-0.68x	-0.77x	-7.53x	-7.27x	-9.43x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	2.02	0.95	1.21	0.88	0.58	0.76

Retornos + indicador ROCE

ROCE más reciente

-82.9%

Prev year -83.6%

Retornos + indicador ROCE table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-54.0%	-111.2%	-85.6%	-118.1%	-87.3%	-147.2%
ROAProfit generated from total assets.	-46.9%	-99.6%	-75.6%	-101.6%	-71.5%	-87.4%
ROICReturn generated on invested operating capital.	-53.9%	-111.4%	-83.4%	-117.4%	-227.0%	-84.5%
ROCEOperating return on long-term capital used.	-53.5%	-110.9%	-83.8%	-116.7%	-83.6%	-82.9%
Earnings YieldEarnings as a percentage of market value.	-16.5%	-62.2%	-51.1%	-12.0%	-12.8%	-11.4%

Calidad del flujo de caja

Calidad del flujo de caja table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-9.05M	$-12.55M	$-7.33M	$-6.82M	$-7.48M	$-8.65M
FCFECash flow available to equity holders after debt flows.	$-9.08M	$-12.55M	$-7.33M	$-6.82M	$-7.48M	$-11.40M
FCF YieldFree cash flow divided by market capitalization.	-12.3%	-59.7%	-42.1%	-8.5%	-8.3%	-7.8%
Income QualityHow well accounting earnings are backed by cash flow.	0.74	0.96	0.82	0.71	0.64	0.66
Capex / OCFShare of operating cash flow spent on capital expenditures.	-0.2%	-0.4%	-0.2%	-0.0%	-1.5%	-0.7%

Eficiencia operativa

Eficiencia operativa table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	117.0d	670.1d	0.0d	254.1d	1903.2d	0.0d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	162.4d	37.6d	541.0d	280.1d	3893.3d	13991.7d
Operating CycleTime from buying inventory to collecting receivables.	117.0d	670.1d	0.0d	254.1d	1903.2d	0.0d
Cash Conversion CycleNet days cash is tied in operations.	-45.5d	632.5d	-541.0d	-26.0d	-1990.1d	-13991.7d

Instantánea

Último / TTM: —

Capitalización

$145.41M

ROE

-147.2%

Rendimiento FCF

-7.8%

Ratio corriente

8.98

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal